These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21367626)

  • 21. Can a tool that automates insulin titration be a key to diabetes management?
    Bergenstal RM; Bashan E; McShane M; Johnson M; Hodish I
    Diabetes Technol Ther; 2012 Aug; 14(8):675-82. PubMed ID: 22568777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 25. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.
    Sambamoorthi U; Garg R; Deb A; Fan T; Boss A
    Curr Med Res Opin; 2017 Jul; 33(7):1309-1316. PubMed ID: 28393573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are glucose readings sufficient to adjust insulin dosage?
    Bashan E; Herman WH; Hodish I
    Diabetes Technol Ther; 2011 Jan; 13(1):85-92. PubMed ID: 21175277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Application of the Food Insulin Index for Mealtime Insulin Dosing in Adults with Type 1 Diabetes: A Randomized Controlled Trial.
    Bell KJ; Gray R; Munns D; Petocz P; Steil G; Howard G; Colagiuri S; Brand-Miller JC
    Diabetes Technol Ther; 2016 Apr; 18(4):218-25. PubMed ID: 26840067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes.
    Racsa PN; Meah Y; Ellis JJ; Saverno KR
    J Manag Care Spec Pharm; 2017 Mar; 23(3):291-298. PubMed ID: 28230457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study.
    Melidonis A; Kamaratos A; Angelidi A; Thomakos P; Vrakas S; Bakalis J; Fousteris E; Iraklianou S
    Diabetes Technol Ther; 2016 Mar; 18(3):159-63. PubMed ID: 26862678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of Continuous Glucose Monitoring (CGM) during Continuous and High-Intensity Interval Exercise in Patients with Type 1 Diabetes Mellitus.
    Moser O; Mader JK; Tschakert G; Mueller A; Groeschl W; Pieber TR; Koehler G; Messerschmidt J; Hofmann P
    Nutrients; 2016 Aug; 8(8):. PubMed ID: 27517956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin glargine or neutral protamine Hagedorn in patients with severe insulin resistance: Is there a benefit?
    Bota VM; Hirsch IB
    Endocr Pract; 2012; 18(3):e49-51. PubMed ID: 22232027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
    Siegmund T; Pfohl M; Forst T; Pscherer S; Bramlage P; Foersch J; Borck A; Seufert J
    Diabetes Metab Syndr; 2017; 11(1):51-57. PubMed ID: 27578616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of fasting capillary glucose variability between insulin glargine and NPH.
    Mu P; Lu H; Zhang G; Chen Y; Fu J; Wang M; Shu J; Zeng L
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e4-7. PubMed ID: 20970870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin therapy in type 2 diabetes.
    Mudaliar S; Edelman SV
    Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.